FDA Finalized Biosimilar Manufacturing Guidance
The new FDA guidance establishes updated regulatory standards for postapproval changes to biosimilar and interchangeable products.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Should the US prioritize international manufacturing standards for domestic biosimilar products?
The FDA has finalized new guidance detailing requirements for postapproval manufacturing changes for biosimilar and interchangeable biosimilar products in the United States. This update aligns domestic regulatory practices with principles set by the International Council for Harmonisation.
Why it matters
The guidance helps harmonize U.S. regulatory standards with international benchmarks, providing clearer pathways for manufacturers to manage changes for interchangeable products. It also streamlines development by refining documentation requirements for new dosage forms and strengths.
The finalized guidance specifically addresses manufacturing adjustments for 351(k) biologics license applications. It dictates that applicants must use well-qualified in-house reference material and evaluate product quality attributes at appropriate process steps.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs and biological products.
International Council for Harmonisation
This global initiative brings together regulatory authorities and the pharmaceutical industry to discuss scientific and technical aspects of drug registration.
The details
The FDA finalized the document entitled Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers to clarify how applicants leverage comparative analytical assessment data. Additionally, the agency updated its 2009 biosimilar development guidance by removing redundant language regarding manufacturing changes.
Timeline
The Biologics Price Competition and Innovation Act was passed in 2009.
The original guidance was issued in 2024.
The final guidance was published in October 2026.
The Tech Race
This move updates the regulatory framework established by the Biologics Price Competition and Innovation Act of 2009. It marks a significant shift toward modernizing how interchangeable biologics are managed, replacing older, redundant protocols with internationally aligned standards.
This guidance simplifies the manufacturing process for biosimilar companies, which may lead to more consistent availability of interchangeable treatments. Patients and providers can expect more standardized quality data to support the safety profile of these products.
The takeaway
The FDA is proactively harmonizing its manufacturing requirements with global standards to support more stable biosimilar production. Manufacturers should review their current comparability exercise protocols to ensure alignment with the newly finalized quality attribute recommendations.
Further reading
For more information on the evolving standards for biologic products, visit the Biotech section.
Source note: This article includes information reported by Raps.
Live Poll
Should the US prioritize international manufacturing standards for domestic biosimilar products?
